<p>，/PRNewswire/ -- 为什么：罗森律师事务所是一家全球投资者权益律师事务所，提醒在 2023 年 8 月 10 日至 2025 年 6 月 25 日期间（包括这两个日期）购买了 Altimmune, Inc.（纳斯达克：ALT）证券的投资者注意 2025 年 10 月 6 日的重要首席原告截止日期。</p>
<p>那么：如果您购买了 Altimmune 的证券，您可能有权在不支付任何自付费用或成本的情况下，通过风险代理安排获得赔偿。</p>
<p>接下来该做什么：要加入 Altimmune 集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=22535 或拨打 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取更多信息。集体诉讼已被提起。如果您希望担任首席原告，必须在 2025 年 10 月 6 日之前向法院提出申请。首席原告是代表其他集体成员进行诉讼的代表方。</p>
<p>为什么选择罗森律师事务所：我们鼓励投资者选择在领导角色中有成功记录的合格律师事务所。通常，发布通知的公司没有可比的经验、资源或任何有意义的同行认可。这些公司中的许多实际上并不进行证券集体诉讼，而只是作为中介，将客户转介给实际进行诉讼的律师事务所。在选择律师时要明智。罗森律师事务所代表全球投资者，专注于证券集体诉讼和股东衍生诉讼。罗森律师事务所曾在当时获得针对一家中国公司的最大证券集体诉讼和解。罗森律师事务所于 2017 年被 ISS 证券集体诉讼服务评选为证券集体诉讼和解数量第一的律师事务所。自 2013 年以来，该事务所每年都排名前四，并为投资者追回了数亿美元。仅在 2019 年，该事务所就为投资者争取了超过 4.38 亿美元。在 2020 年，创始合伙人 Laurence Rosen 被 law360 评选为原告律师界的巨头。该事务所的许多律师已获得 Lawdragon 和 Super Lawyers 的认可。</p>
<p>案件详情：根据诉讼，被告在集体诉讼期间制造了他们拥有关于 Altimmune 的 IMPACT 2b MASH 试验结果的可靠信息的虚假印象。实际上，Altimmune 未能达到与纤维化减少主要终点相关的重要统计显著性指标。Altimmune 一贯夸大其 IMPACT 2b MASH 试验的积极顶线结果的期望，同时隐瞒了安慰剂组的更高反应，这些反应他们知道或应该知道会对顶线结果产生负面影响。Altimmune 的 IMPACT 2b MASH 试验结果与现实不符，正如 Altimmune 的顶线数据所示，显示纤维化减少主要终点未达到统计显著性。当真实细节进入市场时，诉讼声称投资者遭受了损失。</p>
<p>要加入 Altimmune 集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=22535 或拨打 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取更多信息。</p>
<p>尚未认证集体。在集体被认证之前，除非您聘请律师，否则您不受律师的代表。您可以选择自己选择的律师。您也可以保持缺席集体成员身份，此时不采取任何行动。投资者分享任何潜在未来赔偿的能力并不依赖于担任首席原告。</p>
<p>请关注我们的 LinkedIn 更新：https://www.linkedin.com/company/the-rosen-law-firm，Twitter：https://twitter.com/rosen_firm 或 Facebook：https://www.facebook.com/rosenlawfirm/。</p>
<p>律师广告。之前的结果并不保证类似的结果。</p>
<p>联系信息：</p>
<p>Laurence Rosen 律师。</p>
<p>Phillip Kim 律师。</p>
<p>罗森律师事务所，P.A.。</p>
<p>275 Madison Avenue, 40th Floor</p>
<p>纽约，NY 10016</p>
<p>电话：（212）686-1060</p>
<p>免费电话：（866）767-3653</p>
<p>传真：（212）202-3827</p>
<p>[email protected]</p>
<p>www.rosenlegal.com</p>
<p>来源：罗森律师事务所，P.A.。</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwOTAxJk5ld3NJdGVtSWQ9REM2MjUyNiZUcmFuc21pc3Npb25fSWQ9MjAyNTA5MDExMTMzUFJfTkVXU19VU1BSX19fX19EQzYyNTI2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwOTAxJk5ld3NJdGVtSWQ9REM2MjUyNiZUcmFuc21pc3Npb25fSWQ9MjAyNTA5MDExMTMzUFJfTkVXU19VU1BSX19fX19EQzYyNTI2"/></p>

<p>罗森律师事务所提醒在 2023 年 8 月 10 日至 2025 年 6 月 25 日期间购买了 Altimmune, Inc.（纳斯达克代码：ALT）证券的投资者，注意 2025 年 10 月 6 日是发起集体诉讼的截止日期。该诉讼声称 Altimmune 错误地陈述了其 IMPACT 2b MASH 试验的结果，导致投资者损失。投资者可以在没有前期费用的情况下加入集体诉讼。该事务所在证券集体诉讼方面有着良好的业绩记录，并鼓励投资者选择合格的法律顾问</p>

<p>, /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025, both dates inclusive (the &#34;Class Period&#34;), of the important October 6, 2025 lead plaintiff deadline.</p>
<div class="lb-trans"><p>，/PRNewswire/ -- 为什么：罗森律师事务所是一家全球投资者权益律师事务所，提醒在 2023 年 8 月 10 日至 2025 年 6 月 25 日期间（包括这两个日期）购买了 Altimmune, Inc.（纳斯达克：ALT）证券的投资者注意 2025 年 10 月 6 日的重要首席原告截止日期。</p>
</div><p>So What: If you purchased Altimmune securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.</p>
<div class="lb-trans"><p>那么：如果您购买了 Altimmune 的证券，您可能有权在不支付任何自付费用或成本的情况下，通过风险代理安排获得赔偿。</p>
</div><p>What to do next: To join the Altimmune class action, go to https://rosenlegal.com/submit-form/?case_id=22535 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 6, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.</p>
<div class="lb-trans"><p>接下来该做什么：要加入 Altimmune 集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=22535 或拨打 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取更多信息。集体诉讼已被提起。如果您希望担任首席原告，必须在 2025 年 10 月 6 日之前向法院提出申请。首席原告是代表其他集体成员进行诉讼的代表方。</p>
</div><p>Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.</p>
<div class="lb-trans"><p>为什么选择罗森律师事务所：我们鼓励投资者选择在领导角色中有成功记录的合格律师事务所。通常，发布通知的公司没有可比的经验、资源或任何有意义的同行认可。这些公司中的许多实际上并不进行证券集体诉讼，而只是作为中介，将客户转介给实际进行诉讼的律师事务所。在选择律师时要明智。罗森律师事务所代表全球投资者，专注于证券集体诉讼和股东衍生诉讼。罗森律师事务所曾在当时获得针对一家中国公司的最大证券集体诉讼和解。罗森律师事务所于 2017 年被 ISS 证券集体诉讼服务评选为证券集体诉讼和解数量第一的律师事务所。自 2013 年以来，该事务所每年都排名前四，并为投资者追回了数亿美元。仅在 2019 年，该事务所就为投资者争取了超过 4.38 亿美元。在 2020 年，创始合伙人 Laurence Rosen 被 law360 评选为原告律师界的巨头。该事务所的许多律师已获得 Lawdragon 和 Super Lawyers 的认可。</p>
</div><p>Details of the case: According to the lawsuit, defendants throughout the Class Period created the false impression that they possessed reliable information pertaining to the results of Altimmune's IMPACT Phase 2b MASH trial. In truth, Altimmune failed to meet an important statistical significance marker relating to the fibrosis reduction primary endpoint. Altimmune had consistently touted its inflated expectations for positive topline results from the IMPACT Phase 2b MASH trial, while concealing higher responses in the placebo group, which they knew or should have known would negatively impact the topline results. Altimmune's IMPACT Phase 2b MASH trial results fell short of reality, as shown by Altimmune's topline data, which show that the statistical significance was not achieved for the fibrosis reduction primary endpoint. When the true details entered the market, the lawsuit claims that investors suffered damages.</p>
<div class="lb-trans"><p>案件详情：根据诉讼，被告在集体诉讼期间制造了他们拥有关于 Altimmune 的 IMPACT 2b MASH 试验结果的可靠信息的虚假印象。实际上，Altimmune 未能达到与纤维化减少主要终点相关的重要统计显著性指标。Altimmune 一贯夸大其 IMPACT 2b MASH 试验的积极顶线结果的期望，同时隐瞒了安慰剂组的更高反应，这些反应他们知道或应该知道会对顶线结果产生负面影响。Altimmune 的 IMPACT 2b MASH 试验结果与现实不符，正如 Altimmune 的顶线数据所示，显示纤维化减少主要终点未达到统计显著性。当真实细节进入市场时，诉讼声称投资者遭受了损失。</p>
</div><p>To join the Altimmune class action, go to https://rosenlegal.com/submit-form/?case_id=22535 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information.</p>
<div class="lb-trans"><p>要加入 Altimmune 集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=22535 或拨打 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取更多信息。</p>
</div><p>No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.</p>
<div class="lb-trans"><p>尚未认证集体。在集体被认证之前，除非您聘请律师，否则您不受律师的代表。您可以选择自己选择的律师。您也可以保持缺席集体成员身份，此时不采取任何行动。投资者分享任何潜在未来赔偿的能力并不依赖于担任首席原告。</p>
</div><p>Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.</p>
<div class="lb-trans"><p>请关注我们的 LinkedIn 更新：https://www.linkedin.com/company/the-rosen-law-firm，Twitter：https://twitter.com/rosen_firm 或 Facebook：https://www.facebook.com/rosenlawfirm/。</p>
</div><p>Attorney Advertising. Prior results do not guarantee a similar outcome.</p>
<div class="lb-trans"><p>律师广告。之前的结果并不保证类似的结果。</p>
</div><p>Contact Information:</p>
<div class="lb-trans"><p>联系信息：</p>
</div><p>Laurence Rosen, Esq.</p>
<div class="lb-trans"><p>Laurence Rosen 律师。</p>
</div><p>Phillip Kim, Esq.</p>
<div class="lb-trans"><p>Phillip Kim 律师。</p>
</div><p>The Rosen Law Firm, P.A.</p>
<div class="lb-trans"><p>罗森律师事务所，P.A.。</p>
</div><p>275 Madison Avenue, 40th Floor</p>
<div class="lb-trans"><p>275 Madison Avenue, 40th Floor</p>
</div><p>New York, NY 10016</p>
<div class="lb-trans"><p>纽约，NY 10016</p>
</div><p>Tel: (212) 686-1060</p>
<div class="lb-trans"><p>电话：（212）686-1060</p>
</div><p>Toll Free: (866) 767-3653</p>
<div class="lb-trans"><p>免费电话：（866）767-3653</p>
</div><p>Fax: (212) 202-3827</p>
<div class="lb-trans"><p>传真：（212）202-3827</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>www.rosenlegal.com</p>
<div class="lb-trans"><p>www.rosenlegal.com</p>
</div><p>SOURCE The Rosen Law Firm, P.A.</p>
<div class="lb-trans"><p>来源：罗森律师事务所，P.A.。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwOTAxJk5ld3NJdGVtSWQ9REM2MjUyNiZUcmFuc21pc3Npb25fSWQ9MjAyNTA5MDExMTMzUFJfTkVXU19VU1BSX19fX19EQzYyNTI2" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=DC62526&amp;Transmission_Id=202509011133PR_NEWS_USPR_____DC62526&amp;DateId=20250901"/></p>

ALT 投资者有机会主导 Altimmune, Inc.的证券欺诈诉讼